Navigation Links
NeurogesX Reports Fourth Quarter and Year-End 2008 Results
Date:3/20/2009

burn rate; expectations with respect to seeking funding; the potential markets for NeurogesX' product candidates; and the expected benefits of NeurogesX' product candidates;. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, positive results in clinical trials, or the recommendation of the CHMP for MAA approval, may not be sufficient to obtain FDA or European regulatory approval; any regulatory approvals which are received may offer more limited indications than anticipated; unexpected expenses; inability to enter into or obtain adequate funding under commercial or other strategic partnerships; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; physician or patient reluctance to use Qutenza or NGX-1998, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of NeurogesX' product candidates and the advantages of NeurogesX' product candidates over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

                                   NEUROGESX, INC.
                           (A Development Stage Company)

                  CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                  (in thousands, except share and per share data)
                                     (unaudited)

                                     Three Months Ended   Twelve Months Ended
                                    
'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. NeurogesX to Present at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
2. NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results
3. NeurogesX to Present at Susquehanna Financial Groups 2nd Annual SIGnificant Options in Healthcare Conference
4. NeurogesX to Present at RBC Capital Markets 2007 Healthcare Conference
5. NeurogesX to Report Third Quarter 2007 Financial Results on November 14, 2007
6. The NewsHour With Jim Lehrer Reports From South Africa on Renewed Efforts to Combat HIV/AIDS and Tuberculosis
7. Medical symposium highlights importance of case reports -- patient stories in modern medicine
8. Secova Reports Healthcare Provisions In The Stimulus Bill
9. Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports
10. Shamir Optical Industry Ltd. Reports Fourth Quarter and Year-End 2008 Results
11. China Pharma Holdings, Inc. Reports Record 2008 Year End Financial Results and Corporate Updates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014 The 2014 Market ... professional and in-depth research report on COC industry. ... basic information, including its definition, classification, application, industry ... etc. This report also presents product specification, manufacturing ... separated by regions, technology and applications. Analysis also ...
(Date:12/24/2014)... Plantation, FL (PRWEB) December 24, 2014 ... permanent solution for a tooth replacement. They offer the ... boast several advantages over other forms of tooth replacement. ... not rely on the adjacent teeth for support, and ... many people have been told that they are not ...
(Date:12/24/2014)... Dr. Ronald Receveur, a New Albany ... dental implants in a day, has written a ... teeth-whitening treatments. , In his blog published Dec. ... writes that overusing teeth-whitening treatments can lead to tooth ... , “Because teeth-whitening treatments are available in ...
(Date:12/24/2014)... Dec. 23, 2014 (HealthDay News) -- Longer and colder body ... who have brain damage from a lack of oxygen, a ... in newborns with this condition -- called hypoxic ischemic encephalopathy ... 33.5 degrees Celsius (92.3 Fahrenheit) for 72 hours, experts say. ... the brains of animals, so this study examined if the ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 B. E. ... to healthcare providers, has been retained to lead a ... Tri-City Medical Center in Oceanside, Calif. The top ... B. E. Smith has recently placed more than 900 ... is a community owned, 397-bed, Gold Seal-approved, full-service acute-care ...
Breaking Medicine News(10 mins):Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3Health News:Innovative Dental Implant Procedure to Gain Momentum in the New Year 2Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 2Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 3Health News:Greater Cooling of Oxygen-Deprived Infants Fails to Improve Survival 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 3
... new study published in the journal Ultrasound in Obstetrics ... infant survival rate in severe cases of congenital diaphragmatic hernia ... a severe malformation (hole) of the diaphragm and is a ... an incomplete development of the lungs. Researchers led by ...
... FOR DEC. 14, 2011] The two main ways to ... antiviral drugs. A team of investigators has found that ... complement these approaches and reduce mortality among patients hospitalized ... Journal of Infectious Diseases and are now available ...
... Dec. 13 (HealthDay News) -- An older woman,s sleep/wake cycle ... developing dementia, a new study suggests. It found that ... that sometimes precedes dementia) was higher in older women with ... more active later in the day, compared to those who ...
... fluid bathing the brain are linked to poor recovery ... University School of Medicine in St. Louis and the ... "We are particularly interested in finding ways to ... David L. Brody, MD, PhD, assistant professor of neurology ...
... 13, 2011 The American Cancer Society has revised ... consistency, and rigor in creating guidance about cancer ... from the Institutes of Medicine (IOM) by creating ... commissioning systematic evidence reviews, and clearly articulating the ...
... The U.S. Department of Justice filed a proposed consent ... requirements for three major tobacco companies to make internal ... the companies violated the Racketeer Influenced and Corrupt Organizations ... Tobacco Documents Library (LTDL). The order, once approved ...
Cached Medicine News:Health News:Statins may reduce mortality in patients hospitalized with influenza 2Health News:'Body Clock' Might Affect Women's Dementia Risk 2Health News:High levels of tau protein linked to poor recovery after brain injury 2Health News:High levels of tau protein linked to poor recovery after brain injury 3Health News:American Cancer Society revises cancer screening guideline process 2Health News:UCSF to receive tobacco papers, funding to improve public access to the documents 2
(Date:12/22/2014)...   TRU-D SmartUVC LLC, producers of the ... today that the General Services Administration has awarded the ... This newly formed agreement will allow TRU-D ... purchasers, including Department of Veteran Affairs and Department of ... purchasing solutions for the Ebola effort in ...
(Date:12/22/2014)... Dec. 22, 2014  ConvaTec, a privately-held medical products ... been appointed Interim Chief Executive Officer of the company, ... Ken Berger .  "The Board of Directors of ... ConvaTec over the past three years," said Magnus ... "We are confident that the company is well positioned ...
(Date:12/22/2014)... , Dec. 22, 2014 Swedish Orphan ... today announced that the Committee for Medicinal Products for ... has adopted a positive opinion for the use of ... men with Peyronie,s disease with a palpable plaque and ... start of therapy. The use of Xiapex ...
Breaking Medicine Technology:TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
The TCM400 is the first and only portable instrument to provide up to six simultaneous measurements of transcutaneous oxygen tension (tcpO2)...
Two separate sensors provide continuous measurement of tcpO2/tcpCO2 and SpO2....
... the only online source of nationally accredited ... care nurses and other healthcare professionals., ,Radiometers ... you can take them at your convenience. ... is issued upon course completion. The curriculum ...
... components that comprise the SmartPill GI ... comprise the SmartPill GI Monitoring System: ... Receiver software and SmartPill MotiliGI software. ... indispensable parts of the SmartPill GI ...
Medicine Products: